Evaluate the Effects of Renal Impairment on the Pharmacokinetics and Pharmacodynamics

NCT05323136 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic decision

Conditions

ACS - Acute Coronary Syndrome

Interventions

DRUG: MT1002 for Injection

Sponsor

Shaanxi Micot Pharmaceutical Technology Co., Ltd.